

MANAGING RISK

Presentation to the Baltimore/DC Regulatory Affairs Professionals Society (RAPS) June 22, 2006

Cathy St. Hilaire Life Sciences Research Office Center for Health Risk Analysis



What is risk?

• The *likelihood* of an event that may adversely affect human health and the *severity* of the adverse effect



Risk Assessment

Risk assessment provides a formalized process to evaluate human, animal, and ecological responses associated with exposure to potential hazards



Risk Assessment

The purpose of risk assessment is to answer two related questions:

How likely is an adverse event to occur?If it does, how severe will the impact be?



Risk Assessment in the US

• The science of risk assessment evolved out of the necessity to make public health decisions in the face of scientific uncertainty

Risk Assessment in the US

LSRO

 Its basic propositions have been established over the past three decades and its applications have impacted virtually every aspect of public health and environmental protection



History of Risk Assessment

• Qualitative assessment of the strength of the evidence or likelihood that agent A causes disease B



Qualitative Risk Assessment

Koch's Postulates (1894)—defines the scientific evidence required to demonstrate causation for infectious diseases



Koch's Postulates

- An organism can be isolated from a host suffering from the disease
- The organism can be cultured in the laboratory
- The organism causes the same disease when introduced into another host
- The organism can be re-isolated from that host



Qualitative Risk Assessment

Bradford-Hill Criteria (1965)—Criteria to be applied to establish causality between an environmental exposure to a noninfectious agent and a particular disease in humans



Bradford-Hill Criteria

- Is there a temporal relationship?
- How strong is the association between exposure and disease?
- Is there a dose-response relationship?
- Have the results been replicated?
- Is the association biologically plausible?



Bradford-Hill Criteria

- Have alternative explanations been considered?
- What is the effect of ceasing exposure?
- Does the association exhibit specificity?
- Are the findings consistent with other relevant knowledge?



Qualitative Risk Assessment

• Yes/No evaluation—does agent A cause disease B?



Risk Assessment in the Federal Government

 Regulatory agencies had responsibility to protect human health from hazards due to exposures from food (FDA), medical products (FDA), the environment (EPA), the work place (OSHA), consumer products (CPSC)




Risk Assessment and Risk Management

- Risk assessment—the characterization of the potential adverse effects of human exposure to hazards
- Risk management—the process of evaluating alternative actions to control risk and selecting among them

LSRO

Steps in Risk Assessment

- Hazard identification—does a substance cause adverse effects?
- Dose-response assessment—what is the relationship between dose and adverse effect(s)?
- Exposure assessment—What is the nature and degree of exposure to the substance?
- Risk characterization—Given steps 1-3, what is the level of risk?





1900-1970s: Risk Assessment/Management Zero Risk

- *Non-carcinogens*: Identify the "no-effect" dose level
- Apply appropriate "safety factor" to derive "safe/acceptable" dose for humans
- *Carcinogens*: Considered to have no threshold; poses risk at all dose levels
- No exposure permitted

LSRO

Quantitative Risk Assessment

- Necessary when a zero-risk approach is not feasible
- 1970's: FDA developed quantitative methods and policies based on the concept of *de minimis* risk
- Sensitivity of the method guidelines defined "not detected" as the level of a carcinogen in foods that posed 1X10⁻⁶ risk

Quantitative Risk Assessment

- EPA's original approach to carcinogens in the environment was to ban them
- That is, the qualitative demonstration that a chemical is carcinogenic in animal studies was sufficient
- 1970's: Zero-risk was an "unobtainable" goal

LSRO

• Acceptable risk of 1X10⁻⁶ was set



Scientific Uncertainty

- Gaps in scientific information and/or understanding are encountered in risk assessment
- Scientific judgments are needed
- In the absence of 'consensus judgments,' policy is used to fill the gap—usually public-health conservative assumptions are used (reasonable worst-case)



EPA Cancer Guidelines

-1976—4 FR pages
-1986—16 FR pages
-1996-2005—52 FR pages

And OMB wants more....



A New Paradigm

- The International Market Place
- ISO
- Terminology and Approaches



 Risk Management: systematic application of management policies, procedures and practices to the tasks of analyzing, evaluating, and controlling risk



 Risk Analysis: systematic use of available information to identify hazards and to estimate the risk

(= Risk Assessment in EPA paradigm)



 Risk Evaluation: judgment of whether a risk is 'acceptable'*

(Risk Management in EPA paradigm)

* Safety is defined as freedom from unacceptable risk




 Risk Assessment: overall process comprising a risk analysis and a risk evaluation



Risk Control: process which identifies and implements measures to reduce or maintain risks at a specified level

(Risk Management in EPA paradigm)





Risk Analysis

- Identify intended use/intended purpose
- Identify hazard
- Estimate risk



Risk Evaluation

- Is the risk acceptable?
- Does benefit outweigh risk?



Risk Control

Option analysis

• Implementation

• Residual risk evaluation


• Overall risk acceptance



Post-Production Information

Post-production experience

• Review of risk management experience





Ranking Degree of Hazard

<u>Type of data</u>	High score	Medium score	Low score
Acute toxicity	Lethal dose ≤ 50 mg/kg	Lethal dose 50-500 mg/kg	Lethal dose ≥ 50 mg/kg
Chronic toxicity	NOEL ≤ 10 mg/kg	NOEL 10- 1000 mg/kg	NOEL ≥ 1000 mg/kg
Type of chronic effect	Serious, irreversible	Major organ pathology	Minor biologic changes
Route of exposure	Same route	Only by other routes	No relevant routes
Source of information	Humans	Animals	Unconfirmed effects




GHTF Risk Ranking Parameters

Severity of harm		Probability of occurrence	
S-5	Catastrophic	O- 6	Always
S-4	Critical	O-5	Frequent
S-3	Serious	O-4	Probable
S-2	Minor	O-3	Occasional
S-1	Negligible	O-2	Remote
		O- 1	Improbable
		O-0	None



GHTF Risk Chart

0-6					
O-5					
				HIGH	
O-4					
O-3			MID		
O-2					
O-1		LOW			
O-0					
	S-1	S-2	S-3	S-4	S-5





Acceptable Risk

General rule of thumb:

Margin of safety ≥100-fold less than NOEL Cancer risk ≤ 1 x 10-6

MOS

- Chronic NOEL for chemical A is 5mg/d
- EPA derived a reference dose of 0.05 mg/d = 50µg/d
- Worst-case exposure is estimated to be 5µg/d
- MOS is 10

LSRO

• If no 'official' acceptable dose available, use NOEL—MOS should be ≥100



Risk Calculation

Assumptions:

- EPA unit risk estimate = $7.8 \times 10^{-6} \mu g/kg$ bw
- Worst-case average daily dose over lifetime
 (LADD) = 54 μg/day

LADD=54 μ g/ 70 kg=0.77 μ g/kg bw • Lifetime cancer risk=7.8 x 10⁻⁶ μ g/kg x 7.7x10⁺¹ μ g/kg = 6.1 x 10⁻⁵



Application: Regulation-Driven

• CALIFORNIA'S Proposition 65

LSRO

Prop 65

- Ballot initiative—1987
- Anyone doing business in the state
- Carcinogens and reproductive toxicants
- Chemical lists
- Safe harbor numbers
- Warning requirements
- Enforced by AG
- Bounty hunter provision



Compliance

- Each company
- Each product
- Manufacturing facility environmental releases
- Safe harbor numbers were average daily doses/exposures
 - Carcinogens: LADD equivalent to 1X10⁻⁵
 - Reproductive toxicants: Average daily dose on the day of exposure, 1000-fold safety factor required



Risk Management Process

- Management responsibility
- Assemble a team
- Develop a systematic review process



Phase I

- Management
 - Quality Assurance
 - Law Department
- Team
 - QA and Legal
 - Analytical, purchasing, process engineers, risk assessors, toxicologists

LSRO

Risk Management Process

- Identify Prop 65 substances of potential concern for products sold in CA
- Prioritize issues: product/substance pairs
- Develop a database
- Review available analytical data
- Determine regulatory limit to be used
- Perform risk assessments



Steps 1 & 2: Product/Hazard Identification

• Systematic review process

- Start with the Prop 65 list
- Products that could possibly contain X



Prioritize substance/product pairs based on presence in product:

• Known

- Likely
- Possible
- Unlikely
- N/A (drugs, e.g.)



Substance	Known	Likely	Possible	Unlikely
C-1		X (product)	X (product)	
C-2	X (product)			
R-1				Х

Develop Parameters for RA

LSRO

- Known and likely S/P pairs analyzed for presence of Prop 65 substance(s)
- Develop daily intake levels—LADD or ADD; product categories or specific products (USDA data)
- Identify 'acceptable intake levels' based on CA values, EPA values, other 'official' values, toxicological data




Step 3 Sample Calculation

Concentration of S x Intake of P = (L)ADD

 $10 \ \mu g/kg \ x \ .056 \ kg = 5.6 \ \mu g$

Is 5.6 µg/day ≤ Acceptable Daily Intake?





Identify & record control measures

What is the source of S?

- Raw material?
- Ingredient?
- Processing?



Identify & record control measures

What changes can be made to reduce S?


- Tighten specs on raw material?
- Substitute a different ingredient?
- Modify processing?
- Combination of above?



Implement, record & verify control measures

- Implement controls

 Supplier
 Production
 - Product monitoring plan





Is reassessment necessary?

Are there new substances on Prop 65 list?

Are there new safe harbor numbers?

New products/process should trigger Prop 65 review

Changes affecting existing products (new supplier, reformulation) trigger Prop 65 review.



Life Cycle Analysis

- Ensuring the health of the public throughout the total product life cycle
- Design
- Engineering
- Mode of action
- Clinical sciences
- Quality systems
- Post-marketing surveillance



Life Cycle Analysis: Product

- Ensuring the health of the public throughout the total product life cycle
 - Design
 - Engineering
 - Mode of action
 - Clinical sciences
 - Quality systems
 - Post-marketing surveillance
 - Obsolescence



Life Cycle Analysis: Environmental Issues

- Product Applications and Release Diagram (PARD)
 - PARD depicts each step in life of a product: manufacture, storage and distribution, use, and disposal
 - Graphically reveals every point at which exposures to products and potential risks occurs



Environmental Issues

- Prioritize issues
 - Rank hazard/toxicity
 - Rank population exposures
- Human risks
- Ecological risks

LSRO

Ranking Degree of Hazard

Type of data	High score	Medium score	Low score
Acute toxicity	Lethal dose	Lethal dose	Lethal dose
	≤ 50 mg/kg	50-500 mg/kg	≥ 50 mg/kg
Chronic	NOEL	NOEL 10-	NOEL ≥
toxicity	≤ 10 mg/kg	1000 mg/kg	1000 mg/kg
Type of	Serious,	Major organ	Minor biologic
chronic effect	irreversible	pathology	changes
Route of exposure	Same route	Only by other routes	No relevant routes
Source of information	Humans	Animals	Unconfirmed effects



Population Exposures

Type of data	High score	Mid score	Low score
Monitoring	Frequent	Occasional	None
Production volume/Use	Major/ Widespread	Minor/No consumer	None/None
Phys/chem	Volatile, soluble	Poor vol, sol	Not vol, sol
Bioaccum	Fat soluble	Lo soluble	No soluble
Exp media	multimedia	One medium	Insignificant
Population	Most of pop	Subpops	None



Human & Ecological Health

 If risks are excessive (exceed acceptable levels) at any point in the process—risk management begins

• If inadequate information exists, research should be considered



Risk Communication

- Critical, beyond scope of this discussion
- Must be based on substantive risk assessment and management program
- Risk perceptions/nature of the risk



Product Liability/Toxic Torts

- Demonstrate that all care has been taken to understand and manage a product's risks—'due diligence'
- Must be based on substantive risk assessment and management program